CCP
PRQR icon

Clough Capital Partners’s ProQR Therapeutics PRQR Stock Holding History

Clough Capital Partners’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-216,200
Closed -$3.15M – 224
2015
Q3 		$3.15M Buy
+216,200
New +$3.62M 0.14% 116

Other funds holding PRQR

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

Clough Capital Partners's PRQR Position: Q4 2015 in Review

Clough Capital Partners sold out of ProQR Therapeutics (PRQR) in Q4 2015, closing a stake of 216,200 shares — an estimated $3.15M sold.

Clough Capital Partners first reported a position in PRQR in Q3 2015 and held it in 1 quarter. The position peaked at $3.15M in Q3 2015. 32 funds tracked by Wall St. Rank hold PRQR as of Q4 2015.

  • Clough Capital Partners reported no remaining ProQR Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Clough Capital Partners sold 216,200 ProQR Therapeutics shares in Q4 2015, an estimated $3.15M.
  • Clough Capital Partners first reported a position in ProQR Therapeutics in Q3 2015 and held it in 1 quarter.
  • Clough Capital Partners's ProQR Therapeutics position peaked at $3.15M in Q3 2015.
  • 32 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2015.

Based on Clough Capital Partners's 13F filing for Q4 2015, filed 16 Feb 2016.